British Pharmacological Society Cambridge Symposia. 5-7 January 2000, Cambridge, UK [0.03%]
英国药理学杂志剑桥专题研讨会。2000年1月5日到7日，英国剑桥
K Lawson
K Lawson
This meeting covered a broad range of pharmacological topics, although the main themes were covered in four mini-symposia. This report concentrates on the cannabinoid, pain and cardiac ischemia symposia. The cannabinoid system was identifie...
Promises and pitfalls of therapeutics to modify oxidant balance in chronic disease [0.03%]
慢性疾病氧化平衡治疗的利与弊
G Perry,M A Smith
G Perry
BIO-1211 (Biogen) [0.03%]
百健公司的BIO-1211
G T Bolger
G T Bolger
Biogen, in collaboration with Merck & Co, is developing late activator VLA-4 (alpha4beta1) integrin antagonists for the potential treatment of inflammatory conditions [271194]. Merck has begun phase II trials with the lead compound, BIO-121...
TCH-346 (Novartis) [0.03%]
诺华TCR-346
D Mück-Seler,N Pivac
D Mück-Seler
TCH-346, an anti-apoptotic compound, is under development by Novartis for the potential treatment of Parkinson's disease (PD) and motor neuron disease [271447,342937]. By September 1999, phase I clinical trials for PD were underway [342937]...
R A Lewis
R A Lewis
Berlex Biosciences is investigating several series of Factor Xa inhibitors aimed at the prevention and treatment of thrombotic disorders [297584]. Some compounds are based on the structure of ZK-805412, a Z,Z-2,7-bis(dibenzylidene)cyclohept...
J L Marshall,S Baidas,P Bhargava et al.
J L Marshall et al.
R Singh,R G Micetich
R Singh
H A Mucke
H A Mucke
Millennium Pharma Summit--strategic planning to increase growth and generate pharmaceutical shareholder value. 26-27 January 2000, London, UK [0.03%]
千年医药产业高峰会——制定策略加速增长及创造医药企业股东价值会议，2000年1月26-27日，英国伦敦
C Worker,A Kibble
C Worker
With mergers and acquisitions (M&As) being the 'watch words' of the moment among those involved in the pharmaceutical industry, this meeting aimed to bring together the senior hierarchy of both medium and big pharma to discuss the issues pe...
New trends in clinical and experimental immunosuppression--fourth international conference. 17-20 February 2000, Geneva, Switzerland [0.03%]
临床和实验免疫抑制的新趋势——第四届国际会议。2000年2月17～20日，日内瓦，瑞士
L Adorini
L Adorini
The meeting covered several aspects of currently used immunosuppressive drugs, but focused on tolerance induction strategies in the treatment of both allograft rejection and autoimmune diseases. Topics discussed included: clinical trials wi...